Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-a (TNF-a) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-a and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-a and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.
Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-a (TNF-a) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-a and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-a and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients. Thiazolidinediones (TZDs) are insulin sensitizers that decrease plasma glucose (PG) and improve lipid profile in type 2 diabetes mellitus (T2DM) patients. 1 TZDs initiate their action by binding to peroxisome proliferator-activated receptor-g (PPARg). 1 Although PPARg receptors are most abundant in fat cells, 1, 2 they have also been demonstrated in kidney in mesangium and glomerulus. 3, 4 Studies in rodents suggest that TZDs can prevent diabetic nephropathy, 3, 5, 6 and reduction in microalbuminuria has been demonstrated in T2DM patients treated with TZDs in open-labeled trials. 7, 8 Inhibition of transforming growth factor-b 1 and genes involved in collagen/fibronectin formation and reduced serum/renal interstitial tumor necrosis factor-a (TNF-a) levels 9, 10 have been suggested as potential mechanisms for renoprotective effect of TZDs, 3 but the precise mechanism(s) via which TZDs reduce albuminuria is yet to be defined. Adiponectin, whose secretion is enhanced by TZDs, reduces TNF-a levels, suppresses inflammatory actions of TNF-a, 11 enhances endothelium-dependent/independent vasodilation, stimulates nitric oxide (NO) production, and inhibits endothelial cell proliferation. 12, 13 These vascular effects of adiponectin could contribute to reduced albuminuria in T2DM patients treated with TZDs. Elevated plasma free fatty acid (FFA) levels 14 and insulin resistance 15, 16 also have been associated with microalbuminuria, the precursor of diabetic nephropathy.
In this study, we examined the effect of rosiglitazone (RSG) on urinary albumin excretion and related the decrease to changes in insulin sensitivity and circulating adipocytokines in T2DM patients. This represents the first placebocontrolled study to examine the effect of TZDs on microalbumin excretion and relate observed changes to changes in insulin sensitivity and circulating adipocytokines, which potentially could influence renal microalbumin excretion.
fat mass (FM), and fat-free mass (FFM). The metformintreated group had higher (Po0.05) HbA1C and FPG compared to placebo-and RSG-treated groups. There were no significant differences in plasma FFA, leptin, adiponectin, and TNF-a concentrations between RSG and placebo groups before treatment. Serum creatinine concentration and urinary albumin-to-creatinine ratio (UACR) were similar in placebo, RSG, and metformin groups.
Effect of RSG on urinary albumin-to-creatinine ratio, 24-h urinary albumin excretion, and 24-h creatinine clearance A 12 weeks treatment of RSG reduced UACR by À8.771.7 mg/mg (Po0.01 vs baseline and vs placebo (D ¼ þ 4.372.9 mg/mg)). RSG significantly reduced 24-h urinary albumin by À8.673.2 mg/day (Po0.05 vs baseline and vs placebo (D ¼ 3.476.5 mg/day)) without change in 24-h creatinine clearance (117712 to 114713 ml/min). In the placebo group, neither the 24-h urinary albumin excretion rate (23.276.8 to 26.779.5 mg/day) nor the 24-h creatinine clearance (113714 to 100711 ml/min) changed significantly from baseline. Metformin had no effect on UACR (10.271.8 to 9.071.7 mg/mg, P40.50 vs RSG). Serum creatinine and blood pressure did not change in RSG or placebo groups (Table 2 ) or in the metformin group.
Effect of RSG on physiologic and metabolic parameters
After 12 weeks of RSG, there were significant increases in body weight, body mass index, FM, high-density lipoprotein cholesterol and significant decreases in HbA1C and FPG (all Po0.001 vs baseline and vs placebo; Table 2 ). There were no significant changes from baseline in any parameter in the placebo group. During oral glucose tolerance test (OGTT), mean PG (283712 to 23679 mg/dl) and FFA (561733 to 424735 mEq/l) decreased (Po0.001 vs baseline and vs placebo) without change in plasma insulin following RSG (Table 2 ).
In the metformin-treated group, decreases in HbA1C (10.470.5 to 7.770.4%), FPG (232712 to 150711 mg/dl), and mean PG during OGTT (326713 to 22471 mg/dl; all Po0.001 vs baseline) were significantly greater (Po0.05-0.01) than in RSG-treated group.
Effect of RSG on circulating adipocytokines
Following RSG fasting plasma FFA (Po0.01 vs baseline and vs placebo) and TNF-a (Po0.05 vs baseline and vs placebo) concentrations decreased, while fasting plasma adiponectin increased (Po0.001 vs baseline and vs placebo; Table 2 ). Fasting plasma leptin increased (Po0.01) following RSG, but the change was not significantly different from placebo group. Metformin had no effect on fasting plasma FFA.
Euglycemic insulin clamp
Before treatment, steady-state (90-120 min time period) PG (9171 vs 8971 mg/dl) and insulin (7376 and 6574 mU/ml) concentrations were similar in RSG and placebo groups. After 12 weeks of RSG and placebo, PG and insulin concentrations were similar to those during pretreatment insulin clamp.
Before treatment, basal endogenous glucose production (EGP) was similar in RSG (3.2670. 15 Figure 1 ). Percentage changes in FM, plasma leptin, mean blood pressure, and creatinine clearance did not correlate with percentage change in UACR. In backward stepwise multiple regression analysis using the above parameters as independent variables, only percentage changes in fasting TNF-a (standard coefficient ¼ 0.36, Po0.05) and adiponectin (standard coefficient ¼ À0.57, Po0.01) were significantly and independently correlated with percentage change in UACR (r 2 ¼ 0.59, Po0.01). Similar correlations were observed if the absolute values for the change in urinary albumin excretion were related to the absolute change in the parameters of interest.
With respect to metabolic parameters, change in fasting plasma adiponectin was correlated with changes in EGP (r ¼ À0.41, Po0.05) and glucose MCR (r ¼ 0.48, Po0.01) during insulin clamp and with mean PG during OGTT (r ¼ À0.43, Po0.05). Change in mean plasma FFA concentration during OGTT was correlated with changes in EGP (r ¼ 0.43, Po0.05) and glucose MCR (r ¼ À0.58, Po0.01) during insulin clamp and with mean PG during OGTT (r ¼ 0.66, Po0.01). Increases in body weight and body fat following treatment correlated with improvements in mean PG during OGTT (r ¼ À0.51, Po0.01), insulin-stimulated glucose disposal during insulin clamp (r ¼ 0.52, Po0.01), and decline in fasting plasma FFA (r ¼ À0.39, Po0.05) and mean plasma FFA during OGTT (r ¼ À0.40, Po0.05). Changes in fasting TNF-a and leptin concentrations did not correlate with changes in EGP or glucose MCR during insulin clamp.
DISCUSSION
In this double-blind, randomized, placebo-controlled study, we examined the relationship between change in urinary albumin excretion and improvement in insulin sensitivity and circulating adipocytokine levels following RSG in T2DM patients. Consistent with previous findings from our laboratory and others, 17, 18 RSG enhanced both peripheral (muscle) and hepatic insulin sensitivity, reduced HbA1C and FPG, and improved glucose tolerance without any change in plasma insulin concentration. Of particular note, 12 weeks of RSG significantly decreased urinary albumin excretion (vs both baseline and placebo) without any change in systolic or diastolic blood pressure. The reduction in urinary albumin excretion following RSG was associated with improved metabolic control (FPG and insulin sensitivity) and decreased circulating adipocytokine levels (TNF-a, adiponectin, and FFA). However, in stepwise linear regression analysis, only decreased TNF-a and increased adiponectin concentrations were significantly and independently correlated with the decrease in UACR.
In rodents, TNF-a mRNA in glomeruli is increased, 19, 20 and elevated plasma TNF-a concentrations have been related to development of diabetic nephropathy. 9, 14 Increased serum and renal interstitial TNF-a levels also have been demonstrated in diabetic nephropathy in rodents and humans. 9, 10 Diabetic nephropathy also has been associated with NO deficiency. 12, 21 Since adiponectin enhances NO production 22, 23 and since adiponectin levels are markedly reduced in T2DM patients, this raises the possibility that adiponectin deficiency may contribute to development of diabetic nephropathy. Moreover, many studies, 24, 25 including the present one, have demonstrated that TZDs increase plasma adiponectin concentrations to supranormal levels. Since adiponectin suppresses inflammatory actions of TNF-a 11 and enhances endothelium-dependent/independent vasodilation and NO production, 11 this provides a potential mechanism via which TZDs reduce urinary albumin excretion. Many studies have demonstrated that transforming growth factor-b in mesangial cells plays an important role in pathogenesis of diabetic nephropathy. 19 Cultured mesangial cells express PPARg, 4 and it has been suggested that PPARg activation in mesangial cells by TZDs improves diabetic nephropathy via inhibition of transforming growth factor-b, independent of any glucose-lowering effect. 5 The decrement in urinary albumin excretion following RSG also correlated with improved peripheral (muscle) insulin sensitivity. Although reduction in UACR also correlated with decreases in FPG and HbA1C, in a stepwise linear regression analysis, only changes in plasma adiponectin and TNF-a independently correlated with decreased UACR. These observations, combined with our failure to observe any reduction in UACR in T2DM patients treated with metformin to achieve even greater reductions in HbA1C/FPG, argue against a role for improved glycemic control as the mediator of decreased urinary albumin excretion following RSG.
Previous studies have demonstrated a strong association between microalbuminuria and insulin resistance. 15, 16, 26 It has been suggested that the compensatory hyperinsulinemic response to insulin resistance causes renal vasodilation, elevated glomerular hydrostatic pressure gradient, and augmented glomerular filtration rate, resulting in increased albumin excretion. However, we failed to observe any relationship between fasting/post-glucose-load plasma insulin concentrations and UACR either before or after RSG. Our results suggest that the association between improved insulin sensitivity and decreased UACR most likely results from an insulin-sensitizing effect of RSG on adipocytes, 12 leading to inhibition of TNF-a and FFA release and to increased adiponectin secretion.
Several studies have demonstrated that TZDs reduce blood pressure 8, 27 and Bakris et al. 8 attributed the decrease in UACR in RSG-treated diabetic patients to the fall in blood pressure. However, all diabetic patients in this study were normotensive prior to RSG, we did not observe any blood pressure change following RSG, and no correlation was found between change in UACR and either absolute or change in blood pressure. A recent meta-analysis of randomized control trials of RSG in T2DM patients 28 found no significant changes in systolic or diastolic blood pressure. Therefore, it seems unlikely that reduced blood pressure can explain the decrease in microalbumin excretion in this study.
T2DM individuals are characterized by day-long elevated plasma FFA levels due to resistance of fat cell to antilipolytic effect of insulin. Consistent with previous studies from our laboratory, 18, 25 RSG reduced fasting FFA concentration and mean FFA during OGTT by 20 and 24%, respectively, and the reduction in plasma FFA concentration correlated with the decreases in FPG, mean PG during OGTT, and impaired hepatic and peripheral (muscle) insulin sensitivity. These results suggest that the insulin-sensitizing action of TZDs is mediated, at least in part, by their FFA-lowering effect, that is reversal of lipotoxicity. The reduction in FFA also correlated with the decrease in UACR, but this correlation was lost in multiple regression analysis.
Following RSG, plasma adiponectin increased in every diabetic subject by a mean of 2.6-fold, and the increment in plasma adiponectin was strongly correlated with increments in both hepatic and peripheral (muscle) insulin sensitivity. We previously reported similar results in a completely separate group of T2DM subjects. 25 We demonstrated that RSG enhanced IRS-1 tyrosine phosphorylation, association of IRS-1 with phosphatidylinositol 3 0 kinase, and phosphatidylinositol 3 0 kinase activity in the muscle of T2DM patients. 18 The improvement in insulin signaling was closely correlated with reduction in plasma FFA concentration. Since the increase in plasma adiponectin in the present study was strongly related with reduction in plasma FFA, one could postulate that the primary effect of adiponectin is to inhibit lipolysis in adipocytes and/or increase fatty acid oxidation in muscle, 29 leading to decreased intracellular fatty acid metabolites (i.e., fatty acyl CoA, diacylglycerol, and ceramides) and enhanced insulin signaling. 30, 31 Alternatively, adiponectin may have a direct effect on the insulin-signaling cascade. 32 In summary, 12 weeks of RSG treatment significantly decreased urinary albumin excretion without change in blood pressure. Reduction in UACR was correlated with (i) decreased plasma FFA and TNF-a levels, (ii) increased plasma adiponectin concentration, and (iii) enhanced peripheral tissue (muscle) insulin sensitivity. Only decreased TNF-a and increased adiponectin were related to reduced urinary albumin excretion, using multivariate analysis. These results suggest that RSG, either acting directly on renal PPARg receptors or indirectly by altering adipocytokine release from fat cells, causes a reduction in urinary albumin excretion. TZDs may prove useful in preventing diabetic nephropathy in T2DM patients.
MATERIALS AND METHODS
Twenty-nine type 2 diabetic patients were recruited from the outpatient clinic of Texas Diabetes Institute. Patients previously treated with insulin or TZDs were excluded. For subjects treated with angiotensin-converting enzyme (ACE) inhibitors (n ¼ 4) or calcium channel blockers (n ¼ 1), dose was kept constant throughout the study. Clinical and laboratory characteristics of RSG and placebo groups are shown in Table 1 . A separate group of 13 T2DM subjects (age ¼ 5272 years, body mass index ¼ 3071, FPG ¼ 232712 mg/dl, and HbA1C ¼ 10.470.5%) received openlabeled metformin and served as controls for improved glycemic control. Patients were in good health without evidence of cardiac, hepatic, renal, or other chronic diseases as determined by history, physical examination, and routine blood chemistries. Body weight was stable (71.5 kg) for X3 months before study. No subject participated in heavy or formal exercise program. Subjects gave signed voluntary, informed consent prior to participation. The protocol was approved by IRB of UTHSCSA.
Study design
The study had double-blind, placebo-controlled, parallel design for RSG vs placebo groups. Subjects who were taking metformin or sulfonylurea had the medication discontinued 6 weeks before study. All subjects participated in single-blind, 6-week, placebo run-in, during which FPG was measured weekly. Only subjects with o5% variability in PG during last 3 weeks of this run-in period were randomized to RSG or placebo. Fasting plasma lipids and HbA1C were measured every 2 weeks during run-in period. A 24-h urine sample for measurement of urinary creatinine and albumin concentrations was obtained after the 6-week run-in period. On the day of the 24-h urine collection, blood pressure was measured after 5 min in supine position (mean of three determinations) and after 5 min in sitting position (mean of three determinations), using an automated blood pressure recording system (Dynamap, Colin Medical Instruments, San Antonio, TX, USA). During the week before randomization, subjects received (i) 75 g OGTT, (ii) measurement of lean body and FM with 3 H 2 O, and (iii) euglycemic insulin clamp with [3- 3 H]glucose to quantitate hepatic and peripheral tissue insulin sensitivity. Studies were carried out in post-absorptive state at 0800 hours after 10-to 12-h overnight fast. Following completion of these studies, subjects were randomized to receive 12 weeks of RSG, 8 mg/day, or placebo at breakfast. Subjects returned to Clinical Research Center at 0800 hours every 2 weeks for measurement of FPG and body weight. Fasting lipids and HbA1C were measured monthly. During the last week of double-blind period, OGTT, euglycemic insulin clamp, and 24-h urine sample for urinary creatinine and albumin measurements were repeated.
Diabetic patients treated with open-labeled metformin participated in a protocol similar to that described above.
24-h urine collection
At 0800 hours, subjects voided and discarded the urine sample. All subsequent urine samples were collected and stored in a container kept under refrigeration. On the following morning, subjects reported to CRC at 0800 hours and a final urine sample was obtained.
OGTT PG, FFA, and insulin concentrations were measured at À30, À15, and 0 min. At time 0, subjects ingested 75 g of glucose in orangeflavored water, and PG, FFA, and insulin were measured at 15-min intervals for 2 h. At time 0, 100 mCi 3 H 2 O bolus was given intravenously; plasma tritiated water radioactivity was measured at 90, 105, and 120 min for calculation of FFM and FM. 33 Euglycemic insulin clamp Insulin sensitivity was assessed with euglycemic insulin clamp. 34 At 0800 hours (À180 min), a prime (25 mCi Â FPG/100)-continuous (0.25 mCi/min) infusion of H]glucose was started via catheter placed into antecubital vein and continued throughout the study. A second catheter was inserted retrogradely into a vein on the dorsum of hand, which was placed in a heated box (601C). Baseline arterialized venous blood for determination of plasma [3- 3 H]glucose radioactivity and plasma glucose/insulin concentrations was drawn at À30, À20, À10, À5, and 0 min. At time 0, primecontinuous (40 mU/min m 2 ) infusion of regular insulin (Novolin, Novo Nordisk, Princeton, NJ, USA) was started and continued for 120 min. Plasma glucose was allowed to drop to 90 mg/dl, and it was maintained at this level by adjusting a 20% dextrose infusion. Throughout insulin clamp, blood was drawn every 5 min for plasma glucose determination. Plasma insulin concentration and [3- 3 H]glucose specific activity were measured every 10-15 min.
Assays
Plasma glucose was measured using the glucose oxidase method (Glucose Analyzer; Beckman Instruments, Fullerton, CA, USA) and plasma insulin by radioimmunoassay (Diagnostic Products, Los Angeles, CA, USA). HbA1C was measured by affinity chromatography (Biochemical Methodology, Drower 4350; Isolab, Akron, OH, USA) and plasma FFA by enzymatic colorimetric quantification (Wako Chemicals, Neuss, Germany). Plasma total cholesterol and triglyceride were measured enzymatically (Boehringer-Mannheim, Indianapolis, IN, USA) on a Hitachi 704 autoanalyzer. High-density lipoprotein cholesterol was measured enzymatically on the Hitachi 704 autoanalyzer after precipitation of chylomicrons and very low-density lipoprotein and low-density lipoprotein cholesterol by phosphotungstic acid. Low-density lipoprotein cholesterol was calculated from Friedewald equation. Tritiated glucose specific activity was determined in deproteinized plasma samples. TNF-a concentration was determined with the sandwich ELISA kit (detection limit ¼ 0.5 pg/ml; intra-and inter-assay coefficients of variation (CVs) of 5.7 and 7.5%; Quantikine; R&D Systems, Minneapolis, MN, USA). Plasma leptin and adiponectin concentrations were determined by radioimmunoassay (Linco Research, St Charles, MO, USA). Urinary creatinine concentration was measured with the modified Jaffe method, and urinary albumin concentration was determined by radioimmunoassay (Diagnostic Products).
Calculations
Under post-absorptive conditions, rate of endogenous glucose appearance (R a ) equals rate of glucose disappearance, and is calculated as [3- 3 H]glucose infusion rate (d.p.m./min) divided by steady-state plasma [3- 3 H]glucose specific activity (d.p.m./mg). During insulin clamp, non-steady conditions prevail and R a was calculated from Steele's equation. EGP was calculated as R a minus exogenous glucose infusion rate. Total glucose disposal equals sum of residual EGP plus exogenous glucose infusion rate. Total body glucose metabolic clearance rate (MCR) equals total glucose disposal rate divided by plasma glucose concentration.
Total body water was determined from mean plasma 3 H 2 O radioactivity at time 90, 105, and 120 min after intravenous bolus of 3 H 2 O. Plasma 3 H 2 O specific activity was calculated assuming plasma volume represents 93% of total volume. FFM was calculated by dividing total body water by 0.73. 35 Areas under the curve (AUCs) for glucose, insulin, and FFA during OGTT were determined using the trapezoidal rule. Mean PG, insulin, and FFA concentrations during OGTT were calculated by dividing area under the curve by 120 min.
Statistical analysis
The statistical analysis was performed with StatView for Windows (SAS Institute, Cary, NC, USA). Values before and after treatment within each group were analyzed using paired Student's t-test.
Comparison between groups was performed using analysis of variance with Bonferroni/Dunn post hoc testing. Pearson's correlations between continuous variables were used as a measure of association. Stepwise multiple linear regression analysis was performed to examine multiple correlations among variables. Data are presented as mean7s.e. P-value o0.05 was considered statistically significant.
